CLINICAL_TRIALS
trial_result
· 2024-09-19
Clinical Trial Update: Phase IV Clinical Study of Recombinant Mycobacterium Tuberculosis Fusion Protein [Phase 4]
Summary
A Phase 4 trial evaluating a recombinant Mycobacterium tuberculosis fusion protein for latent tuberculosis infection has been completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Conditions: Latent Tuberculosis Infection | Phase 4 | Status: COMPLETED